Loss of Homeostatic Microglia Signature in Prion Diseases
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index; 49 of the 115 sources its claims cite were checked for support.
Abstract
Prion diseases are neurodegenerative diseases that affect humans and animals. They are always fatal and, to date, no treatment exists. The hallmark of prion disease pathophysiology is the misfolding of an endogenous protein, the cellular prion protein (PrPC), into its disease-associated isoform PrPSc. Besides the aggregation and deposition of misfolded PrPSc, prion diseases are characterized by spongiform lesions and the activation of astrocytes and microglia. Microglia are the innate immune cells of the brain. Activated microglia and astrocytes represent a common pathological feature in neurodegenerative disorders. The role of activated microglia has already been studied in prion disease mouse models; however, it is still not fully clear how they contribute to disease progression. Moreover, the role of microglia in human prion diseases has not been thoroughly investigated thus far, and specific molecular pathways are still undetermined. Here, we review the current knowledge on the different roles of microglia in prion pathophysiology. We discuss microglia markers that are also dysregulated in other neurodegenerative diseases including microglia homeostasis markers. Data on murine and human brain tissues show that microglia are highly dysregulated in prion diseases. We highlight here that the loss of homeostatic markers may especially stand out.
Overview
CoChat Summary
TL;DR
This review argues that microglia are highly dysregulated in prion diseases, with a striking loss of homeostatic markers such as TMEM119 and P2RY12, especially in the thalamus, alongside activation and proliferation. It proposes a time-dependent dual role: early microglial activation may help clear PrPSc, whereas prolonged proinflammatory signaling and increased proliferation at later stages are harmful.
Key findings
- In murine prion disease, reactive microglia appear before symptoms, around day 70–80 in a region-dependent manner, mainly in the thalamus; terminal disease shows bushy/amoeboid morphology and significantly increased microglia numbers, highest in the thalamus.
- Homeostatic microglia proteins TMEM119 and P2RY12 are significantly reduced in terminal prion disease; the signature is still abundant in hippocampus but almost completely lost in thalamus, especially for P2RY12.
- In human sCJD, TMEM119 protein is significantly reduced, and the loss of this homeostatic marker appears more severe than in AD; CD68 is increased in sCJD frontal cortex compared with AD.
- Microglia may have a dual role: suppressing microglia proliferation in the clinical phase prolonged survival in mice, while partial depletion early enhanced prion accumulation and accelerated disease; complete depletion accelerated disease without enhanced PrPSc accumulation.
- RML mouse model timing: incubation to terminal disease about 150 days ± 5 days; infectious prions detectable around 30 dpi, PrPSc by Western blot after about 60 dpi, symptoms around day 90. sCJD incidence is 1–2 per million people per year.
Methods
- Narrative review of current knowledge on microglia in prion pathophysiology, including murine prion models and human sCJD.
- The authors present staining examples of different microglial markers in prion mouse models and human sCJD, and synthesize findings from cited transcriptomic, immunohistochemical, and functional studies.
- Main analysis is qualitative integration of data across prion strains (e.g., RML, 22L, ME7), brain regions, disease stages, and human tissues; no new systematic meta-analysis is reported.
Limitations
- Stated: the role of microglia in human prion diseases has not been thoroughly investigated, specific molecular pathways remain undetermined, and it is still unclear whether microglia contribute mainly through gain of detrimental functions, loss of protective homeostatic support, or both.
- Stated: discrepancies between P2ry12 RNA expression and protein loss remain unresolved; further experiments including mass spectrometry at different disease stages are needed, and larger patient sets are warranted for sCJD/AD comparisons.
- Stated: the transmissible nature and biosafety issues of prion disorders limit use of single-cell/nuclear sequencing in human prion disease. Evident: as a review, conclusions rely on heterogeneous cited models, stages, and regions rather than a systematic primary dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Prion disease course in the mouse model. Prion diseases are neurodegenerative diseases that can be easily experimentally transmitted by the inoculation of mouse-adapted prions (such as the Rocky Mountain Laboratory strain; RML inoculum) to the brains of mice. Disease onset and clinical course are relatively accurately predictable, eventually leading to terminal disease usually within 150 ± 5 days after high-dose intracerebral inoculation. RML 5.0 is a specific and very well-characterized passage of RML that was and is used in several laboratories [35]. After a latency period, in this model, prion infectivity is already detectable in the brain at 30 days post infection (dpi), and misfolded PrPSc can be detected by Western blot (WB) at around 60 dpi. Symptoms appear around 90–100 dpi. Lower panel: The pan-microglia/monocyte marker ionized calcium-binding adaptor molecule 1 (IBA1) is shown at 80 dpi in different brain regions in comparison to the brain of a mock-infected control mouse (healthy brain). Note the region-specific change towards a reactive microglia phenotype in the thalamus in prion disease during the preclinical stage before the onset of symptoms, including an increase in microglia numbers [45,46,47]. Scale bar: 100 µm.](https://figures.cochat.ai/paper-figures/18195bd71ff649cfa86eb0dd5fb0b8d1/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-2.jpg)
![Figure 3 Microglia are highly activated in terminal prion disease. The pan-microglia/macrophage marker IBA1 is shown in mouse brain sections of (A) mock-infected healthy mice and (B) RML 5.0 prion-infected mice at a terminal disease state. (A) Microglia in the healthy brain show a ramified phenotype with a small soma and thin processes in all four regions displayed here (see magnified close-up). (B) During the terminal prion disease stage, microglia massively proliferate (see overview) and change their morphology towards bigger cell bodies and thicker arms (see close-ups) with a bushy appearance in the hippocampus and an amoeboid phenotype in the thalamus [45,46,47]. Scale bar: 100 µm; close-up: 50 µm.](https://figures.cochat.ai/paper-figures/cf42988cdc394ef095bffbd6b6179cce/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-3.jpg)
![Figure 4 Loss of microglial homeostatic phenotype in terminal prion disease. The microglia-specific homeostasis markers P2RY12 and TMEM119 show a ramified morphology of microglia in the healthy brain [47,73,97]. In terminal prion disease, this homeostatic microglia signature is lost in a region-dependent manner [47,73,97]. While the activated microglia in the dentate gyrus of the hippocampus display a bushy morphology with thick and retracted processes and still express both markers, microglia in the thalamus (posterior complex) have almost completely lost the expression of the markers, especially P2RY12. In the RML-prion mouse model, the deposition of PrPSc-specific staining is stronger in the thalamus than in the hippocampus in terminal prion disease. Scale bar: 25 µm.](https://figures.cochat.ai/paper-figures/af1240828f1d4c978289d35a831aaa6e/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-4.jpg)
![Figure 5 Loss of microglia homeostatic phenotype and increase in gliosis upon terminal prion disease. (A) IBA1 (green) and TMEM119 (red) co-localize in the hippocampus and thalamus in the healthy mouse brain, highlighting the ramified morphology with fine processes mainly stained by TMEM119 [47,73,97]. TMEM119 is highly reduced (white arrowhead) in the dentate gyrus of the hippocampus, and completely lost (white arrowhead) in the thalamus (posterior complex) in terminal prion disease [73]. Scale bar: 20 µm. (B) IBA1 (microglia/green) and GFAP (astrocytes/red) show intense dysregulation and are in close proximity (white asterisks) in the healthy brain and in terminal prion disease. (DAPI/nucleus in blue) [73]. Scale bar: 20 µm.](https://figures.cochat.ai/paper-figures/908390a5992a46dba8559929d7b9507e/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-5.jpg)
![Figure 6 Glia cells are highly dysregulated in human sCJD. Human brain tissues are usually fixed in 4% buffered formalin. To inactivate prion infectivity, tissues should be incubated in 98% formic acid for 1.5 h. Tissues from healthy human controls should be similarly treated with formic acid, to enable identical staining conditions. Frontal cortex and cerebellum brain sections from sCJD patients and control patients without neurologic disease are shown for (A) the pan-microglia/macrophage marker IBA1 and homeostatic microglia marker TMEM119 [97]. Note that while IBA1+ microglia are increased in sCJD staining, the intensity of TMEM119 staining is reduced compared to an age-matched non-demented control patient [97]. Deposits of misfolded PrPSc (sCJD) are also shown. Scale bar: 200 µm. (B) Besides microglia, astrocytes are also highly dysregulated in prion diseases such as sCJD [97,107], as displayed by the astrocyte markers GFAP and YKL-40 for an sCJD case and an age-matched control. Scale bar: 200 µm.](https://figures.cochat.ai/paper-figures/362a5ae09a934cbab0f3208b27c7341d/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-6.jpg)
![Figure 7 Disease-associated microglia profile differs between human sCJD and AD. Frontal cortex tissue of a sCJD patient and an age-matched AD patient show reactivity for the pan-microglia/macrophage marker IBA1, the microglial marker TMEM119, and the activation marker CD68 [97]. Deposits of misfolded proteins are shown for the respective antibodies against amyloid-β (AD) or PrPSc (sCJD). Note that the deposition pattern of misfolded PrPSc may vary considerably between CJD patients (see also Figure 6). In contrast to AD, microglia activation is more prominent and the microglial homeostasis marker is almost completely lost in sCJD [97]. Scale bar: 50 µm.](https://figures.cochat.ai/paper-figures/0844f8a2c05f4efb8ac1de84d350d243/loss-of-homeostatic-microglia-signature-in-prion-diseases-figure-7.jpg)
Verification
Claims the paper makes
22 Valid · 1 Not valid · 49 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several proinflammatory cytokines are upregulated in the brain during the prion disease course including TNF α, IL 1α, and C1qa [46,69,70,71,72,73].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Partly supportedcites [46] Carroll, 2018, Microglia Are Critical in Host Defense against Prion Disease, J. Virol. sourceExperimental — accuracy not yet measured
The Results (page unavailable) say several proinflammatory genes were increased in mouse brain during scrapie at 80 days post-infection, and Table 2 includes Il1a and Tnf among the genes assessed. Our copy does not identify C1qa as upregulated, and its evidence concerns a specified time point rather than the entire disease course. (LLM, conf=0.87)
- Not checked yetcites [69] Riemer, 2004, Gene expression profiling of scrapie-infected brain tissue, Biochem. Biophys. Res. Commun. source
- Not checked yetcites [70] Carroll, 2015, Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction, J. Virol. source
- Partly supportedcites [71] Vincenti, 2015, Defining the Microglia Response during the Time Course of Chronic Neurodegeneration, J. Virol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports increased Tnfa expression and a proinflammatory microglial response during prion disease. It names Il1b, not Il1a, among the increased cytokines, and the passages found do not establish increased C1qa expression. Thus this source supports the general point and TNF α example, but not the other two named examples. (LLM, conf=0.88)
- Partly supportedcites [72] Hwang, 2009, A systems approach to prion disease, Mol. Syst. Biol. sourceExperimental — accuracy not yet measured
The Results sections on PrPSc accumulation and microglial/astrocytic activation report increased C1qa/b mRNA and describe cytokine responses during prion infection. They do not identify TNF-α or IL-1α as upregulated, and they place C1qa in a complement pathway rather than identifying it as a cytokine. Page numbers are not available in our copy. (LLM, conf=0.86)
- Supportedcites [73] Hartmann, 2019, Complement 3(+)-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia, Acta Neuropathol. Commun. source
The Introduction states that TNF-α, IL-1α, and C1qa are upregulated in the brain during the disease course in mouse prion disorders. The Discussion reiterates their upregulation in mouse models of prion disease; the claim is supported for that setting. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“while another stimulator of inflammation, the bacterial lipopolysaccharide (LPS), could not further stimulate their PrPSc-degrading function during disease progression [81].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Supportedcites [81] Hughes, 2010, Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation, Glia source
The Conclusion states that secondary LPS challenge in ME7 prion-diseased animals, whether systemic or intracerebral, did not stimulate more efficient PrPSc clearance despite increased inflammation. The Results section likewise reports no significant PrPSc clearance near the intracerebral LPS injection site. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, microglia morphology is changed from the ramified presentation typical in homeostasis to a bushy/reactive or even amoeboid morphology in a region-dependent manner (Figure 3A,B) [45,46,47].”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Partly supportedcites [45] Fransen, 2013, Regulation of microglial proliferation during chronic neurodegeneration, J. Neurosci. sourceExperimental — accuracy not yet measured
The section “The inhibition of microglial mitosis alters the inflammatory activation state” (page unavailable) reports larger microglial cell bodies and thicker processes in prion-diseased mice after AraC treatment. It does not establish a ramified-to-bushy or amoeboid change in untreated terminal disease. The “Time course of microglial proliferation” section reports regional differences in cell numbers, not morphology. (LLM, conf=0.78)
- Partly supportedcites [46] Carroll, 2018, Microglia Are Critical in Host Defense against Prion Disease, J. Virol. sourceExperimental — accuracy not yet measured
The Introduction and Discussion report microglial activation during prion disease, and the Discussion notes regional influences on microglial subpopulations. However, our copy does not describe a change from ramified to bushy or amoeboid morphology at terminal disease, or establish that such a change varies by region (searched: ramified, bushy, amoeboid, morphology). (LLM, conf=0.78)
- Partly supportedcites [47] Muth, 2017, Activation of microglia by retroviral infection correlates with transient clearance of prions from the brain but does not change incubation time, Brain Pathol. sourceExperimental — accuracy not yet measured
The Results section (‘Microglia homeostasis is severely disturbed in clinical prion disease’; page unavailable) reports highly activated microglia and region-dependent loss of the homeostatic marker P2ry12 in clinically prion-diseased mice. It does not describe a transition from ramified to bushy or amoeboid morphology, so the specific morphological claim is unsupported by this paper. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, microglia are directly activated by PrPSc in vitro [33,59]; however, such causalities are difficult to prove in vivo.”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Not checked yetcites [33] Giese, 1998, Role of microglia in neuronal cell death in prion disease, Brain Pathol. source
- Supportedcites [59] Srivastava, 2018, Inflammatory response of microglia to prions is controlled by sialylation of PrP(Sc), Sci. Rep. source
The Results section on primary microglia reports that purified PrPSc significantly increased inflammatory markers and concludes that it can directly trigger an inflammatory response. The Methods section describes the in vitro exposure of cultured primary microglia and BV2 cells to purified PrPSc. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The same outcome was recently published after region-specific bulk transcriptomic analyses of brains infected with two different prion strains [74]. Although these strains target different cell populations in the brain, the regional glia response was comparable.”
§ Loss of Homeostatic Microglia Signature in Prion Diseases > 1. Introduction > 1.1. Microglia Are Dysregulated and May Have a Dual Role in Prion Diseases
What the sources say
- Supportedcites [74] Makarava, 2020, Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism, Neurobiol. Dis. source
The Introduction describes gene-expression analysis of four mouse brain regions infected with the astrocyte-associated 22L or neuron-associated ME7 strain, using a NanoString neuroinflammation panel. The Discussion reports the same neuroinflammation signature for both strains across the regions, although its timing and degree of activation differed. The analysis used a targeted panel, not whole-transcriptome sequencing. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 9 with their cited sources checked
Create a free account to see all 84 claims and to verify the 66 references still open.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 17
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Activated microglia represent a common feature of neurodegenerative diseases [54,66,67].”
BackgroundResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 2×
“As mention above, microglia in the healthy brain display a homeostatic morphology characterized by a small c ll body and l ng branching processes which are constantly surveying their enviro m nt [61].”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“and others have identified a disease-specific microglia signature that is commonly dysregulated in brain diseases including AD [55,101].”
BackgroundFate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Novel Proteinaceous Infectious Particles Cause Scrapie
Prusiner, S. B. (1982) · Science · doi:10.1126/science.6801762 · Cited by 5,118 · cited 2×
“formation and disease progression [18] (Figure 1A).”
BackgroundSynaptic Pruning by Microglia Is Necessary for Normal Brain Development
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T. A., Guiducci, E., Dumas, L., et al. (2011) · Science · doi:10.1126/science.1202529 · Cited by 4,244 · cited 2×
“The targeting of unwan d ele e ts for remov involves complement receptors and adaptor proteins, among other signals [62,64].”
BackgroundKettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 1×
“The latter enables microglia to increase their phagocytic capacity to remove unwanted structures and to release proinflammatory mediators including cytokines and chemokines [65].”
BackgroundThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 2×
“The targeting of unwan d ele e ts for remov involves complement receptors and adaptor proteins, among other signals [62,64].”
BackgroundKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 4×
“Fittingly, we found that the loss of the homeostatic signature is especially severe i prion diseases compared t other neurodegenerative conditions [47,55].”
BackgroundSelf-citationNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“It has been shown to play a fundamental role in Alzheimer’s disease (AD) pathophysiology [78,79].”
BackgroundA new variant of Creutzfeldt-Jakob disease in the UK
Will, R. G., Ironside, J. W., Zeidler, M., Estibeiro, K., Cousens, S. N., Smith, P. G., Alperovitch, A., Poser, S., Pocchiari, M., & Hofman, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91412-9 · Cited by 2,707 · cited 1×
“, for BSE, since BSE has been transmitted to humans in a number of cases, mainly in 129 MM carriers during the BSE crisis, and gave rise to a subtype of CJD, which was termed variant CJD [14,15].”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“Only recently were the molecular and functional characteristics of murine bona fide homeostatic microglia identified by different groups using a set of novel methodologies such as quantitative proteomics or RNA sequencing [88,93,94].”
BackgroundHammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225
Mice devoid of PrP are resistant to scrapie
Büeler, H., Aguzzi, A., Sailer, A., Greiner, R.-A., Autenried, P., Aguet, M., & Weissmann, C. (1993) · Cell · doi:10.1016/0092-8674(93)90360-3 · Cited by 2,100 · cited 2×
“Since PrPC is the essential substrate for the disease-associated PrPSc-templated misfolding cascade, PrPknockout mice are resistant to prion infection and disease [22].”
BackgroundMicroglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999
the Immunological Genome Consortium, Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2419 · Cited by 1,972 · cited 1×
“Only recently were the molecular and functional characteristics of murine bona fide homeostatic microglia identified by different groups using a set of novel methodologies such as quantitative proteomics or RNA sequencing [88,93,94].”
BackgroundMicroglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858 · cited 2×
“Activation can be identified by a combination of morphological and immunophenotypic changes [68].”
BackgroundLocal self-renewal can sustain CNS microglia maintenance and function throughout adult life
Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W., & Rossi, F. M. V. (2007) · Nature Neuroscience · doi:10.1038/nn2014 · Cited by 1,643
Microglial interactions with synapses are modulated by visual experience
Tremblay, M.-È., Lowery, R. L., & Majewska, A. K. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000527 · Cited by 1,542
The microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511 · cited 1×
“Only recently were the molecular and functional characteristics of murine bona fide homeostatic microglia identified by different groups using a set of novel methodologies such as quantitative proteomics or RNA sequencing [88,93,94].”
BackgroundNLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487 · cited 1×
“It has been shown to play a fundamental role in Alzheimer’s disease (AD) pathophysiology [78,79].”
BackgroundMicroglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E. G., Wieghofer, P., Heinrich, A., Riemke, P., Hölscher, C., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3318 · Cited by 1,457 · cited 1×
“Microglia are the innate immune cells of the brain, yet in contrast to their counterparts in peripheral organs, the macrophages, they arise from primitive yolk sack macrophages that colonize the brain early during development [39,40].”
BackgroundThe same prion strain causes vCJD and BSE
Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C. L., Gowland, I., Collinge, J., Doey, L. J., & Lantos, P. (1997) · Nature · doi:10.1038/38925 · Cited by 1,456 · cited 1×
“, for BSE, since BSE has been transmitted to humans in a number of cases, mainly in 129 MM carriers during the BSE crisis, and gave rise to a subtype of CJD, which was termed variant CJD [14,15].”
BackgroundMicroglial brain region-dependent diversity and selective regional sensitivities to aging
Grabert, K., Michoel, T., Karavolos, M. H., Clohisey, S., Baillie, J. K., Stevens, M. P., Freeman, T. C., Summers, K. M., & McColl, B. W. (2016) · Nature Neuroscience · doi:10.1038/nn.4222 · Cited by 1,151
Scrapie prion protein contains a phosphatidylinositol glycolipid
STAHL, N. (1987) · Cell · doi:10.1016/0092-8674(87)90150-4 · Cited by 1,112 · cited 1×
“PrPC is a glycosylphosphatidylinositol (GPI)-anchored protein that is attached to the outer leaflet of the plasma membrane [19].”
BackgroundA novel progressive spongiform encephalopathy in cattle
Wells, G., Scott, A., Johnson, C., Gunning, R., Hancock, R., Jeffrey, M., Dawson, M., & Bradley, R. (1987) · Veterinary Record · doi:10.1136/vr.121.18.419 · Cited by 1,067
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046 · cited 1×
“However, the identification of microglia-specific profiles was complicated by the lack of understanding of whether and how brain-resident microglia functionally differ from peripheral myeloid cells which might enter the brain in certain instances [92].”
BackgroundMolecular basis of phenotypic variability in sporadc creudeldt‐jakob disease
Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S. G., Farlow, M., Dickson, D. W., Sima, A. A. F., Trojanowski, J. Q., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390613 · Cited by 864 · cited 2×
“The molecular basis for this phenotypic variability is defined by the distinct biochemical properties of the prion protein and an allelic variation in codon 129 (methionine or valine) of the prion protein gene (PRNP) [12,13].”
BackgroundMicroglial Phagocytosis of Live Neurons
Brown, G. C., & Neher, J. J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3710 · Cited by 853 · cited 1×
“Since these studies did not lead to conclusive data about the role of microglia and their putative PrPSc-reducing function, another line of experiments was performed to address the impact of “eat me”-signals on neurons or “eat-me”-receptors on microglia on neuronal survival in prion pathophysiology [83].”
ResultMicroglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew, K., Li, K., Olmos-Alonso, A., Garcia-Moreno, F., Liang, Y., Richardson, P., Tipton, T., Chapman, M. A., Riecken, K., Beccari, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.041 · Cited by 726
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
Caughey, B., & Raymond, G. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55257-1 · Cited by 637 · cited 2×
“Misfolding of t is c llular isoform l ds to the -sheet-enriched and protease-resistant disease conformer PrPSc [20,21].”
BackgroundBruttger, J., Karram, K., Wörtge, S., Regen, T., Marini, F., Hoppmann, N., Klein, M., Blank, T., Yona, S., Wolf, Y., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.012 · Cited by 634
Dysregulation of brain and choroid plexus cell types in severe COVID-19
Yang, A. C., Kern, F., Losada, P. M., Agam, M. R., Maat, C. A., Schmartz, G. P., Fehlmann, T., Stein, J. A., Schaum, N., Lee, D. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03710-0 · Cited by 620
Fatal Familial Insomnia, a Prion Disease with a Mutation at Codon 178 of the Prion Protein Gene
Medori, R., Tritschler, H.-J., LeBlanc, A., Villare, F., Manetto, V., Chen, H. Y., Xue, R., Leal, S., Montagna, P., Cortelli, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260704 · Cited by 606
A new fate mapping system reveals context-dependent random or clonal expansion of microglia
Tay, T. L., Mai, D., Dautzenberg, J., Fernández-Klett, F., Lin, G., Sagar, Datta, M., Drougard, A., Stempfl, T., Ardura-Fabregat, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4547 · Cited by 597
Genetic prion disease: the EUROCJD experience
Kovács, G. G., Puopolo, M., Ladogana, A., Pocchiari, M., Budka, H., van Duijn, C., Collins, S. J., Boyd, A., Giulivi, A., Coulthart, M., et al. (2005) · Human Genetics · doi:10.1007/s00439-005-0020-1 · Cited by 450
Self-citationMapping microglia states in the human brain through the integration of high-dimensional techniques
Sankowski, R., Böttcher, C., Masuda, T., Geirsdottir, L., Sagar, Sindram, E., Seredenina, T., Muhs, A., Scheiwe, C., Shah, M. J., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0532-y · Cited by 449
NBB-Psy, Böttcher, C., Schlickeiser, S., Sneeboer, M. A. M., Kunkel, D., Knop, A., Paza, E., Fidzinski, P., Kraus, L., Snijders, G. J. L., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0290-2 · Cited by 436 · cited 3×
“cfm?abstract_id=4065080) (Accessed on 10 September 2022) [100].”
MethodInfluentialTMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434 · cited 14×
“Frontal cortex and cerebellum brain sections from sCJD patients and control patients without neurologic disease are shown for (A) the pan-microglia/macrophage marker IBA1 and homeostatic microglia marker TMEM119 [97].”
BackgroundInfluentialRegulation of Microglial Proliferation during Chronic Neurodegeneration
Gómez-Nicola, D., Fransen, N. L., Suzzi, S., & Perry, V. H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4440-12.2013 · Cited by 407 · cited 1×
“Moreover, it has been shown that suppression of microglia proliferation in the clinical disease phase significantly prolonged survival in the mouse model [45], suggesting a detrimental role for this cell type at a late disease stage.”
BackgroundTargeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358
Self-citationÜber eine eigenartige herdförmige erkrankung des zentralnervensystems (Vorläufige mitteilung)
Creutzfeldt, H. G. (1920) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02866081 · Cited by 325
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases
Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R., & Collinge, J. (2011) · Nature · doi:10.1038/nature09768 · Cited by 319 · cited 2×
“To date, the mecha isms leading to neurotoxicity and neuronal l ss are only partially understood, yet cellular levels of PrPC seem to critically determine neurotoxicity [23].”
BackgroundJakob, A. (1921) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02870932 · Cited by 316
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291 · cited 1×
“Activated microglia represent a common feature of neurodegenerative diseases [54,66,67].”
BackgroundA systems approach to prion disease
Hwang, D., Lee, I. Y., Yoo, H., Gehlenborg, N., Cho, J., Petritis, B., Baxter, D., Pitstick, R., Young, R., Spicer, D., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.10 · Cited by 287
Orre, M., Kamphuis, W., Osborn, L. M., Melief, J., Kooijman, L., Huitinga, I., Klooster, J., Bossers, K., & Hol, E. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.008 · Cited by 272
Gomi, H., Yokoyama, T., Fujimoto, K., Ikeda, T., Katoh, A., Itoh, T., & Itohara, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90238-4 · Cited by 256
Sobue, A., Komine, O., Hara, Y., Endo, F., Mizoguchi, H., Watanabe, S., Murayama, S., Saito, T., Saido, T. C., Sahara, N., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01099-x · Cited by 253
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Self-citationResenberger, U. K., Harmeier, A., Woerner, A. C., Goodman, J. L., Müller, V., Krishnan, R., Vabulas, R. M., Kretzschmar, H. A., Lindquist, S., Hartl, F. U., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.86 · Cited by 248 · cited 1×
“Toxic signaling of misfolded PrPSc via cellular receptors (with PrPC possibly being one of them) on the neuronal membrane may lead to direct synapto- and neurotoxicity [24,25]; however, non-neuron autonomous pathways may contribute as well.”
BackgroundCodon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease
Alperovitch, A., Zerr, I., Pocchiari, M., Mitrova, E., Cuesta, J. D. P., Hegyi, I., Collins, S., Kretzschmar, H., van Dujin, C., & Will, R. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01342-2 · Cited by 240 · cited 2×
“The molecular basis for this phenotypic variability is defined by the distinct biochemical properties of the prion protein and an allelic variation in codon 129 (methionine or valine) of the prion protein gene (PRNP) [12,13].”
BackgroundRole of microglia in neuronal cell death in prion disease
Giese, A., Brown, D. R., Groschup, M. H., Feldmann, C., Haist, I., & Kretzschmar, H. A. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00167.x · Cited by 239 · cited 1×
“Moreover, microglia are directly activated by PrPSc in vitro [33,59]; however, such causalities are difficult to prove in vivo.”
BackgroundHoriuchi, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.12.3193 · Cited by 226 · cited 2×
“Misfolding of t is c llular isoform l ds to the -sheet-enriched and protease-resistant disease conformer PrPSc [20,21].”
BackgroundKimberlin, R. H., Walker, C. A., & Fraser, H. (1989) · Journal of General Virology · doi:10.1099/0022-1317-70-8-2017 · Cited by 222 · cited 1×
“) with distinct neuropathological features and disease kinetics [29,30].”
BackgroundNeuropathology of prion diseases
Budka, H. (2003) · British Medical Bulletin · doi:10.1093/bmb/66.1.121 · Cited by 196
EVIDENCE FOR AN EARLY INFLAMMATORY RESPONSE IN THE CENTRAL NERVOUS SYSTEM OF MICE WITH SCRAPIE
BETMOUNI, S., PERRY, V. H., & GORDON, J. L. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00212-6 · Cited by 196
Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer’s disease
Kenkhuis, B., Somarakis, A., Kleindouwel, L. R. T., van Roon-Mom, W. M. C., Höllt, T., & van der Weerd, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105684 · Cited by 188
Collins, S. J., McLean, C., & Masters, C. L. (2001) · Journal of Clinical Neuroscience · doi:10.1054/jocn.2001.0919 · Cited by 182
Atypical inflammation in the central nervous system in prion disease
Perry, H. V., Cunningham, C., & Boche, D. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00020 · Cited by 180
The immunobiology of prion diseases
Aguzzi, A., Nuvolone, M., & Zhu, C. (2013) · Nature reviews. Immunology · doi:10.1038/nri3553 · Cited by 166 · cited 1×
“Therefore, prion-infected mice represent a versatile tool to study and understand prion biology [31].”
BackgroundHartmann, K., Sepulveda-Falla, D., Rose, I. V. L., Madore, C., Muth, C., Matschke, J., Butovsky, O., Liddelow, S., Glatzel, M., & Krasemann, S. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0735-1 · Cited by 141 · cited 21×
“While the homeostatic markers are still abundant in the hippocampus, this signature is almost completely lost in the thalamus, an effect which is especially severe for P2RY12 (Figure 4) [47,73,97].”
BackgroundSelf-citationA neuroprotective role for microglia in prion diseases
Zhu, C., Herrmann, U. S., Falsig, J., Abakumova, I., Nuvolone, M., Schwarz, P., Frauenknecht, K., Rushing, E. J., & Aguzzi, A. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151000 · Cited by 134 · cited 3×
“Work on prion-infected organotypic brain-slice cultures support the prion clearing and neuroprotective functions of microglia [50].”
BackgroundBaker, C. A., Martin, D., & Manuelidis, L. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10905-10913.2002 · Cited by 128 · cited 1×
“This is in line with findings showing that microglia isolated from the brains of prion-infected mice are infectious [58].”
ResultAguzzi, A., & Zhu, C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90605 · Cited by 122 · cited 1×
“In contrast, reducing microglia numbers by knocking out interleukin 34 (IL-34), an essential signaling molecule, led to augmented PrPSc deposition and shortened survival in a prion mouse model [50,51], while the inhibition of IL-34 resulted in reduced microglia proliferation [52].”
BackgroundKranich, J., Krautler, N. J., Falsig, J., Ballmer, B., Li, S., Hutter, G., Schwarz, P., Moos, R., Julius, C., Miele, G., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092401 · Cited by 110 · cited 1×
“Accordingly, the knockout of MFGE8 accelerated disease but this was restricted to certain mouse models [84].”
BackgroundGene expression profiling of scrapie-infected brain tissue
Riemer, C., Neidhold, S., Burwinkel, M., Schwarz, A., Schultz, J., Krätzschmar, J., Mönning, U., & Baier, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.124 · Cited by 108
Incidence of Creutzfeldt-Jakob disease in Switzerland
Glatzel, M., Rogivue, C., Ghani, A. C., Streffer, J. R., Amsler, L., & Aguzzi, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09384-4 · Cited by 108 · cited 1×
“The most common human prion disease is sporadic CJD (sCJD) with an incidence of 1–2 per million people per year [11].”
BackgroundSelf-citationReview on the epidemiology and dynamics of BSE epidemics
Ducrot, C., Arnold, M., de Koeijer, A., et al. (2008) · Veterinary Research · doi:10.1051/vetres:2007053 · Cited by 107
Microglia Are Critical in Host Defense against Prion Disease
Carroll, J. A., Race, B., Williams, K., Striebel, J., & Chesebro, B. (2018) · Journal of Virology · doi:10.1128/jvi.00549-18 · Cited by 94 · cited 1×
“Moreover, partial depletion of microglia in early stages of the disease was reported to enhance the accumulation of prions in the brain and accelerate the onset of clinical disease [46].”
BackgroundHughes, M. M., Field, R. H., Perry, V. H., Murray, C. L., & Cunningham, C. (2010) · Glia · doi:10.1002/glia.21070 · Cited by 94
Carroll, J. A., Striebel, J. F., Rangel, A., Woods, T., Phillips, K., Peterson, K. E., Race, B., & Chesebro, B. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005551 · Cited by 92 · cited 2×
“Despite these obvious differences, highly similar expression patterns in neuroinflammatory genes and glia response genes were measured in all three mouse models [75].”
BackgroundDefining the Microglia Response during the Time Course of Chronic Neurodegeneration
Vincenti, J. E., Murphy, L., Grabert, K., McColl, B. W., Cancellotti, E., Freeman, T. C., & Manson, J. C. (2016) · Journal of Virology · doi:10.1128/jvi.02613-15 · Cited by 88
Cunningham, C., Deacon, R. M. J., Chan, K., Boche, D., Rawlins, J. N. P., & Perry, V. H. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.015 · Cited by 86 · cited 1×
“) with distinct neuropathological features and disease kinetics [29,30].”
BackgroundPrion pathogenesis in the absence of Toll-like receptor signalling
Prinz, M., Heikenwalder, M., Schwarz, P., Takeda, K., Akira, S., & Aguzzi, A. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor731 · Cited by 85 · cited 1×
“In the RML infection mouse model of prion diseases, the incubation time to terminal disease is about 150 days ± 5 days (Figure 2) [36].”
BackgroundJones, E. L., Hummerich, H., Viré, E. A., Uphill, J. B., Dimitriadis, A., Speedy, H. E., Campbell, T., Norsworthy, P. J., Quinn, L. J. E., Whitfield, J. T., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30273-8 · Cited by 82 · cited 1×
“However, variants of PRNP were also identified as a key risk factor for sCJD, besides the recent identification of novel risk loci [16,17].”
BackgroundImmunohistochemical study of microglia in the Creutzfeldt-Jakob diseased brain
Sasaki, A., Hirato, J., & Nakazato, Y. (1993) · Acta Neuropathologica · doi:10.1007/bf00369445 · Cited by 79
Guiroy, D. C., WAKAYAMA, I., Liberski, P. P., & Gajdusek, D. C. (1994) · Acta Neuropathologica · doi:10.1007/bf00294180 · Cited by 78
Astrocyte gene expression in Creutzfeldt-Jakob disease
Manuelidis, L., Tesin, D. M., Sklaviadis, T., & Manuelidis, E. E. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5937 · Cited by 77 · cited 1×
“Another characteristic of prion diseases is the widespread and severe reactive astrogliosis [105].”
BackgroundPrions activate a p38 MAPK synaptotoxic signaling pathway
Fang, C., Wu, B., Le, N. T. T., Imberdis, T., Mercer, R. C. C., & Harris, D. A. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007283 · Cited by 72 · cited 1×
“Toxic signaling of misfolded PrPSc via cellular receptors (with PrPC possibly being one of them) on the neuronal membrane may lead to direct synapto- and neurotoxicity [24,25]; however, non-neuron autonomous pathways may contribute as well.”
BackgroundSubtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt–Jakob Disease
Llorens, F., López-González, I., Thüne, K., Carmona, M., Zafar, S., Andréoletti, O., Zerr, I., & Ferrer, I. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00198 · Cited by 69
RNA-seq and network analysis reveal unique glial gene expression signatures during prion infection
Carroll, J. A., Race, B., Williams, K., Striebel, J., & Chesebro, B. (2020) · Molecular Brain · doi:10.1186/s13041-020-00610-8 · Cited by 66 · cited 2×
“Interestingly, novel investigations in mouse models after microglia depletion have shown that this prion disease-specific astrocyte signature develops without the proinflammatory stimulation provided by microglia [98].”
BackgroundResultMakarava, N., Chang, J. C.-Y., Molesworth, K., & Baskakov, I. V. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104783 · Cited by 64 · cited 1×
“The same outcome was recently published after region-specific bulk transcriptomic analyses of brains infected with two different prion strains [74].”
BackgroundGenome-wide transcriptomics identifies an early preclinical signature of prion infection
Sorce, S., Nuvolone, M., Russo, G., Chincisan, A., Heinzer, D., Avar, M., Pfammatter, M., Schwarz, P., Delic, M., Müller, M., et al. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008653 · Cited by 63
Carroll, J. A., Striebel, J. F., Race, B., Phillips, K., & Chesebro, B. (2015) · Journal of Virology · doi:10.1128/jvi.02952-14 · Cited by 63 · cited 1×
“In addition to the upregulation of PAMPs in prion diseases, the transcription of several genes encoding damage-associated molecular pattern (DAMP) proteins and receptors such as Toll-like receptors or proteins of the complement cascade are also increased in the brains of prion-infected mice [70,82].”
BackgroundScrapie in Mice Deficient in Apolipoprotein E or Glial Fibrillary Acidic Protein
Tatzelt, J., Maeda, N., Pekny, M., Yang, S.-L., Betsholtz, C., Eliasson, C., Cayetano, J., Camerino, A. P., DeArmond, S. J., & Prusiner, S. B. (1996) · Neurology · doi:10.1212/wnl.47.2.449 · Cited by 59 · cited 1×
“Thus, the impact of its knockout on disease pathophysiology was tested several years ago [102,106].”
BackgroundPhenotypic variability in human prion diseases
Ironside, J. W., Ritchie, D. L., & Head, M. W. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00697.x · Cited by 58
Scheckel, C., Imeri, M., Schwarz, P., & Aguzzi, A. (2020) · eLife · doi:10.7554/elife.62911 · Cited by 57 · cited 2×
“Progressive dysregulation of glia cells including microglia could also be demonstrated on the gene expression level using novel techniques [37,38].”
BackgroundMethodBarcikowska, M., Liberski, P. P., Boellaard, J. W., Brown, P., Gajdusek, D. C., & Budka, H. (1993) · Acta Neuropathologica · doi:10.1007/bf00334672 · Cited by 57
Experimental Chronic Wasting Disease (CWD) in the Ferret
Sigurdson, C. J., Mathiason, C. K., Perrott, M. R., et al. (2008) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2008.01.004 · Cited by 54
Self-citationInflammatory response of microglia to prions is controlled by sialylation of PrPSc
Srivastava, S., Katorcha, E., Makarava, N., Barrett, J. P., Loane, D. J., & Baskakov, I. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-29720-z · Cited by 47 · cited 1×
“Moreover, microglia are directly activated by PrPSc in vitro [33,59]; however, such causalities are difficult to prove in vivo.”
BackgroundAccelerated Prion Replication in, but Prolonged Survival Times of, Prion-Infected CXCR3−/−Mice
Riemer, C., Schultz, J., Burwinkel, M., Schwarz, A., Mok, S. W. F., Gültner, S., Bamme, T., Norley, S., van Landeghem, F., Lu, B., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01371-08 · Cited by 45 · cited 1×
“In line with the proposed capacity of microglia to phagocytose PrPSc, the knockout of C-X-C chemokine receptor type 3 (CXCR3) led to accelerated PrPSc accumulation and increased prion infectivity titers, but prolonged survival in the mouse model [76].”
BackgroundZhu, C., Herrmann, U. S., Li, B., Abakumova, I., Moos, R., Schwarz, P., Rushing, E. J., Colonna, M., & Aguzzi, A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.02.019 · Cited by 44
Microglia deficiency accelerates prion disease but does not enhance prion accumulation in the brain
Bradford, B. M., McGuire, L. I., Hume, D. A., Pridans, C., & Mabbott, N. A. (2022) · Glia · doi:10.1002/glia.24244 · Cited by 44 · cited 1×
“Novel data on the complete depletion of brain microglia have shown that mice displayed an accelerated disease course, but did not show an enhanced accumulation of PrPSc [53].”
BackgroundSinha, A., Kushwaha, R., Molesworth, K., Mychko, O., Makarava, N., & Baskakov, I. V. (2021) · Cells · doi:10.3390/cells10071728 · Cited by 42 · cited 1×
“Interestingly, these findings on the loss of homeostatic microglial proteins in terminal prion disease are in contrast to findings on the RNA expression of the corresponding genes, since P2ry12 RNA expression has been shown to be relatively upregulated [98,99].”
ResultPrion Pathogenesis in the Absence of NLRP3/ASC Inflammasomes
Nuvolone, M., Sorce, S., Schwarz, P., & Aguzzi, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117208 · Cited by 39 · cited 1×
“In contrast to AD, the knockout of NLRP3 or the adaptor protein ASC does not influence the prion disease course [80].”
BackgroundAbsence of CD14 delays progression of prion diseases accompanied by increased microglial activation
Sakai, K., Hasebe, R., Takahashi, Y., Song, C.-H., Suzuki, A., Yamasaki, T., & Horiuchi, M. (2013) · Journal of Virology · doi:10.1128/jvi.02072-13 · Cited by 37 · cited 1×
“The knockout of the cluster of differentiation CD14 also led to a prolonged survival with enhanced microglia activation in two different mouse models [77].”
BackgroundGlial activation in prion diseases is selectively triggered by neuronal PrPSc
Lakkaraju, A. K. K., Sorce, S., Senatore, A., Nuvolone, M., Guo, J., Schwarz, P., Moos, R., Pelczar, P., & Aguzzi, A. (2022) · Brain Pathology · doi:10.1111/bpa.13056 · Cited by 34 · cited 1×
“Novel research in mice that exclusively produce PrPSc in neurons or in astrocytes shows that neither drive the dysregulation of glia cells on their own [60].”
BackgroundObst, J., Simon, E., Martin-Estebane, M., Pipi, E., Barkwill, L. M., Gonzalez-Rivera, I., Buchanan, F., Prescott, A. R., Faust, D., Fox, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579000 · Cited by 33
Sánchez‐Juan, P., Bishop, M., Kovács, G. G., Calero, M., Aulchenko, Y. S., Ladogana, A., Boyd, A., Lewis, V., Ponto, C., Calero, O., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123654 · Cited by 32 · cited 1×
“However, variants of PRNP were also identified as a key risk factor for sCJD, besides the recent identification of novel risk loci [16,17].”
BackgroundTREM2 expression in the brain and biological fluids in prion diseases
Diaz-Lucena, D., Kruse, N., Thüne, K., Schmitz, M., Villar-Piqué, A., da Cunha, J. E. G., Hermann, P., López-Pérez, Ó., Andrés-Benito, P., Ladogana, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02296-1 · Cited by 32
Chouhan, J. K., Püntener, U., Booth, S. G., & Teeling, J. L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.760721 · Cited by 24 · cited 1×
“The region-specific increase in microglia numbers during the course of a prion disease had already been shown with several mouse adapted prion strains [45–47] and may be aggravated by systemic infection [48,49].”
BackgroundUnderstanding the natural variability of prion diseases
Geissen, M., Krasemann, S., Matschke, J., & Glatzel, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.041 · Cited by 24
Self-citationMuth, C., Schröck, K., Madore, C., Hartmann, K., Fanek, Z., Butovsky, O., Glatzel, M., & Krasemann, S. (2017) · Brain Pathology · doi:10.1111/bpa.12441 · Cited by 23 · cited 23×
“Moreover, in our recent experiments, the extensive loss of the homeostatic signature in prion diseases stands out remarkably [47,73,97].”
BackgroundMethodInfluentialSelf-citationToll-like receptor 2 confers partial neuroprotection during prion disease
Carroll, J. A., Race, B., Williams, K., & Chesebro, B. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208559 · Cited by 22 · cited 2×
“In addition to the upregulation of PAMPs in prion diseases, the transcription of several genes encoding damage-associated molecular pattern (DAMP) proteins and receptors such as Toll-like receptors or proteins of the complement cascade are also increased in the brains of prion-infected mice [70,82].”
BackgroundGenome-wide transcriptomics identifies an early preclinical signature of prion infectionPreprint
Sorce, S., Nuvolone, M., Russo, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.10.901637 · Cited by 16 · cited 3×
“0 is a specific and very wellcharacterized passage of RML that was and is used in several laboratories [35].”
BackgroundInfluentialSlota, J. A., Medina, S. J., Frost, K. L., & Booth, S. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.918811 · Cited by 16 · cited 2×
“Progressive dysregulation of glia cells including microglia could also be demonstrated on the gene expression level using novel techniques [37,38].”
BackgroundMethodGajdusek, D. C., & Lh, R. (1961) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1961.10.628 · Cited by 15
Pankiewicz, J. E., Lizińczyk, A. M., Franco, L. A., Diaz, J. R., Martá-Ariza, M., & Sadowski, M. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01261-z · Cited by 15 · cited 3×
“However, the deletion of ApoE might influence the course of prion disease including the exacerbation of prion pathology, a dysregulated microglial phenotype, and impaired clearance of PrPSc and dying neurons by microglia [104].”
BackgroundInfluentialPrion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling
Nuvolone, M., Paolucci, M., Sorce, S., Kana, V., Moos, R., Matozaki, T., & Aguzzi, A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177876 · Cited by 13
Areškevičiūtė, A., Litman, T., Broholm, H., Melchior, L. C., Nielsen, P. R., Green, A., Eriksen, J. O., Smith, C., & Lund, E. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010140 · Cited by 13
Krbot, K., Hermann, P., Skorić, M. K., Zerr, I., Sepulveda‐Falla, D., Goebel, S., Matschke, J., Krasemann, S., & Glatzel, M. (2018) · Neuropathology · doi:10.1111/neup.12517 · Cited by 11 · cited 21×
“While the homeostatic markers are still abundant in the hippocampus, this signature is almost completely lost in the thalamus, an effect which is especially severe for P2RY12 (Figure 4) [47,73,97].”
BackgroundResultSelf-citationXia, Y., Chen, C., Chen, J., Hu, C., Yang, W., Wang, L., Liu, L., Gao, L.-P., Wu, Y.-Z., Chen, D.-D., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02989-y · Cited by 7 · cited 2×
“Interestingly, novel data have also shown that MCSF/CSF1R signaling is upregulated in prion infection [57].”
BackgroundInnate Immune Tolerance in Microglia Does Not Impact on Central Nervous System Prion Disease
Pal, R., Bradford, B. M., & Mabbott, N. A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.918883 · Cited by 7 · cited 1×
“The region-specific increase in microglia numbers during the course of a prion disease had already been shown with several mouse adapted prion strains [45–47] and may be aggravated by systemic infection [48,49].”
BackgroundThe role of macrophage scavenger receptor 1 (Msr1) in prion pathogenesis
Li, B., Chen, M., Aguzzi, A., & Zhu, C. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02061-7 · Cited by 7
Unaltered prion disease in mice lacking developmental endothelial locus-1
Zhu, C., Li, Z., Li, B., Pfammatter, M., Hornemann, S., & Aguzzi, A. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.003 · Cited by 4
Aberrant type I and type III collagen gene expression in human breast cancerin vivo
Kauppila, S., Stenbäck, F., Risteli, J., Jukkola, A., & Risteli, L. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(1998110)186:3
Parchi, P., Giese, A., Capellari, S., Brown, P., Schulz-Schaeffer, W., Windl, O., Zerr, I., Budka, H., Kopp, N., Piccardo, P., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<224::aid-ana12>3.0.co;2-w
Cited by
Microglia Signatures: A Cause or Consequence of Microglia-Related Brain Disorders?
Mirarchi, A., Albi, E., & Arcuri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010951 · Cited by 54
“The identified molecular pathways could represent potential therapeutic targets to modulate microglia activity and slow disease progression [123,124].”
BackgroundSynapse vulnerability and resilience across the clinical spectrum of dementias
Taddei, R. N., & Duff, K. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01094-7 · Cited by 27
“Published online: 22 May 2025”
Hay, A. J. D., Popichak, K. A., Mumford, G., Shirley, P. M., Bian, J., Wolfrath, L., Lei, S., Eggers, M., Nicholson, E. M., Tjalkens, R. B., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012582 · Cited by 13
“Microglia scavenge and phagocytose PrP Sc , which results in a phenotypic change from scavenging and ramified to activated and amoeboid, often denoted as a shift from M2 to M1, or homeostatic microglia to disease-associated microglia (DAM) [6,38,40,41,50,54].”
Adipose-derived mesenchymal stromal cells decrease prion-induced glial inflammation in vitro
Hay, A. J. D., Murphy, T. J., Popichak, K. A., Zabel, M. D., & Moreno, J. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-26628-7 · Cited by 13
Pehar, M., Hewitt, M., Wagner, A., Sandhu, J. K., Khalili, A., Wang, X., Cho, J., Sim, V. L., & Kulka, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75982-1 · Cited by 8
“Although many studies have indicated that microglia are involved in prion disease 69–71 , very few studies have investigated PrP C expression in human microglia; we are one of the first to directly show PrP C protein expression in human-derived microglia.”
Background
Metadata
- Authors
- Wang, Y., Hartmann, K., Thies, E., Mohammadi, B., Altmeppen, H., Sepulveda-Falla, D., Glatzel, M., & Krasemann, S.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany
- Corresponding author
- Krasemann, Susanne
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-09-21
- Volume
- 11
- Issue
- 19
- Pages
- 2948
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9563810
- OpenAlex
- W4296991042
- Cited by
- 12
- References
- 122
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2022: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- China Scholarship Council (202108410135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- prion disease, microglia, microglial homeostasis, microglial activation, cellular prion protein, PrPSc, neurodegeneration, astrocytes, microglial markers, neuroinflammation
- MeSH terms
- Prion Proteins, Animals, Homeostasis, Humans, Prions, Prion Diseases, Microglia, Neurodegenerative Diseases, Protein Isoforms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.